cept Therapeutics rporated(US:CORT) 券商中国·2026-01-01 10:46Group 1: Corcept Medical - Corcept Medical's stock plummeted by 50% after the FDA rejected its drug application for treating a rare hormonal disorder, resulting in a market value loss of $3.7 billion [1][3]. - The FDA's complete response letter indicated that while the company's GRACE clinical trial met its primary endpoint, additional evidence of efficacy is required for a favorable benefit-risk assessment [3][4]. - Corcept's CEO expressed disappointment but remains committed to finding a way to bring the drug Relacorilant to patients, planning to meet with the FDA to discuss next steps [3][4]. Group 2: Relacorilant Drug Details - Relacorilant is a selective cortisol modulator aimed at treating conditions like endogenous hypercortisolism and ovarian cancer, and it has orphan drug designation from both the FDA and the European Commission [5][6]. - The drug has shown improvements in various symptoms associated with hypercortisolism, which can lead to serious health issues such as diabetes and hypertension [4][5]. - The FDA has set a target date of July 11, 2026, for the drug's use in treating platinum-resistant ovarian cancer patients [6]. Group 3: Indian Tobacco Market - Indian tobacco stocks experienced significant declines, with ITC's stock dropping over 9% and Godfrey Phillips India falling more than 16% following the announcement of a substantial increase in cigarette consumption tax [1][7]. - The new tax, effective February 1, will impose a consumption tax based on cigarette length, potentially increasing overall costs by 22%-28% for certain products [7][8]. - Analysts predict that the increased tax burden may lead to higher retail prices and could negatively impact cigarette sales, with concerns about a shift to illegal tobacco markets [7][8].